SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge📊Experiments🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo
📖

Ceftriaxone ALS Trial

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-ceftriaxone-als
Related Entities
clinical-trials-ceftriaxone-als
Metadata
slugclinical-trials-ceftriaxone-als
entity_typeclinical
kg_node_idNone
🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

Linked Artifacts (65)
mentions🔬What are the mechanisms underlying tdp-43 phase separation t60%
mentions🔬What are the mechanisms underlying rna binding protein dysre60%
mentions🔬CRISPR-based therapeutic approaches for neurodegenerative di60%
mentions🔬Analyze the spectrum of microglial activation states (DAM, h60%
mentions🔬CRISPR-based therapeutic approaches for neurodegenerative di60%
mentions🔬How do non-cell autonomous effects of autophagy dysfunction 60%
mentions🔬RNA binding protein dysregulation across ALS FTD AD60%
mentions🔬TDP-43 undergoes liquid-liquid phase separation that becomes60%
mentions🔬RNA binding protein dysregulation across ALS FTD and AD60%
related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr60%
related🧫Metabolic Pathway-Targeted Therapy in ALS60%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker60%
related🧫ALS Regional Onset and Spread: Network-Level Staging Model60%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk60%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri60%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring60%
related🧫Brainstem Circuit Modulation for PSP60%
related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT60%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study60%
related🧫Environmental Exposure Causal Attribution in ALS — Experimen60%
related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio60%
related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design60%
related🧫N-of-1 Clinical Trial Design for CBS/PSP60%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers60%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic60%
related🧫Progranulin Replacement Therapy for FTD — Vector Development60%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD60%
related🧫PSP and CBS Biomarker Validation Study60%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen60%
related🧫TDP-43 PET Ligand Development for FTD and ALS60%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des60%
see_also📖entities-gfap60%
related🔬What are the mechanisms underlying tdp-43 phase separation t54%
related🔬What are the mechanisms underlying rna binding protein dysre54%
related🔬CRISPR-based therapeutic approaches for neurodegenerative di54%
related🔬Analyze the spectrum of microglial activation states (DAM, h54%
related🔬CRISPR-based therapeutic approaches for neurodegenerative di54%
related🔬How do non-cell autonomous effects of autophagy dysfunction 54%
related🔬RNA binding protein dysregulation across ALS FTD AD54%
related🔬TDP-43 undergoes liquid-liquid phase separation that becomes54%
related🔬RNA binding protein dysregulation across ALS FTD and AD54%
related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr54%
related🧫Metabolic Pathway-Targeted Therapy in ALS54%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker54%
related🧫ALS Regional Onset and Spread: Network-Level Staging Model54%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk54%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri54%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring54%
related🧫Brainstem Circuit Modulation for PSP54%
related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT54%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study54%
related🧫Environmental Exposure Causal Attribution in ALS — Experimen54%
related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio54%
related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design54%
related🧫N-of-1 Clinical Trial Design for CBS/PSP54%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers54%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic54%
related🧫Progranulin Replacement Therapy for FTD — Vector Development54%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD54%
related🧫PSP and CBS Biomarker Validation Study54%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen54%
related🧫TDP-43 PET Ligand Development for FTD and ALS54%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des54%
mentions🧪GFAP-Positive Reactive Astrocyte Subtype Delineation50%
related🧪APOE-Dependent Autophagy Restoration50%
SciDEX — scidex.ai — Dashboard | Mission Control | Status | How it Works | GitHub